Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation

Shingo Tanaka; Mitsutoshi Nakada; Sumihito Nobusawa; Satoshi O. Suzuki; Hemragul Sabit; Katsuyoshi Miyashita; Yutaka Hayashi

doi:10.1007/s10014-014-0192-2

Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation

Shingo Tanaka, Mitsutoshi Nakada, Sumihito Nobusawa, Satoshi O. Suzuki, Hemragul Sabit, Katsuyoshi Miyashita, Yutaka Hayashi

Pathobiology

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Abstract

Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50 % of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.

Original language	English
Pages (from-to)	172-176
Number of pages	5
Journal	Brain tumor pathology
Volume	31
Issue number	3
DOIs	https://doi.org/10.1007/s10014-014-0192-2
Publication status	Published - Jul 2014

All Science Journal Classification (ASJC) codes

Oncology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10014-014-0192-2

Cite this

@article{f50342ff1eaa4d16b0ed354155d2cbe1,

title = "Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation",

abstract = "Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50 % of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.",

author = "Shingo Tanaka and Mitsutoshi Nakada and Sumihito Nobusawa and Suzuki, {Satoshi O.} and Hemragul Sabit and Katsuyoshi Miyashita and Yutaka Hayashi",

year = "2014",

month = jul,

doi = "10.1007/s10014-014-0192-2",

language = "English",

volume = "31",

pages = "172--176",

journal = "Brain tumor pathology",

issn = "1433-7398",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation

AU - Tanaka, Shingo

AU - Nakada, Mitsutoshi

AU - Nobusawa, Sumihito

AU - Suzuki, Satoshi O.

AU - Sabit, Hemragul

AU - Miyashita, Katsuyoshi

AU - Hayashi, Yutaka

PY - 2014/7

Y1 - 2014/7

N2 - Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50 % of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.

AB - Pleomorphic xanthoastrocytoma (PXA) is classified by the World Health Organization as a grade II astrocytic tumor with relatively favorable prognosis among gliomas. A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (BRAF V600E) mutation, which is commonly found in PXA, has recently been detected in approximately 50 % of all epithelioid glioblastoma (GBM) cases. We herein report a case of epithelioid GBM developing at the site of a left temporal PXA 13 years after the treatment of the primary tumor. The BRAF V600E mutation was detected in both tumors. These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.

UR - http://www.scopus.com/inward/record.url?scp=84905085877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905085877&partnerID=8YFLogxK

U2 - 10.1007/s10014-014-0192-2

DO - 10.1007/s10014-014-0192-2

M3 - Article

C2 - 24894018

AN - SCOPUS:84905085877

SN - 1433-7398

VL - 31

SP - 172

EP - 176

JO - Brain tumor pathology

JF - Brain tumor pathology

IS - 3

ER -

Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this